Screenings went down in all populations except non-metropolitan statistical area communities, showing that a greater understanding of health disparities in these areas is needed.
Meta-analysis found GLP-1 receptor agonist use in these patients was associated with a 29% decrease in risk, though results were not uniform across all studies.
Study reveals how factors such as healthcare access, economic stability and geography contribute to higher rates of the disease, emphasizing the need for focused health policies and interventions.